SE0401031D0 - A new glucocorticoid replacement therapy - Google Patents

A new glucocorticoid replacement therapy

Info

Publication number
SE0401031D0
SE0401031D0 SE0401031A SE0401031A SE0401031D0 SE 0401031 D0 SE0401031 D0 SE 0401031D0 SE 0401031 A SE0401031 A SE 0401031A SE 0401031 A SE0401031 A SE 0401031A SE 0401031 D0 SE0401031 D0 SE 0401031D0
Authority
SE
Sweden
Prior art keywords
glucocorticoid
glucocorticoids
relates
replacement therapy
treatment
Prior art date
Application number
SE0401031A
Other languages
English (en)
Swedish (sv)
Inventor
Stanko Skrtic
Joergen Johnsson
Hans Lennernaes
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Duocort Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duocort Ab filed Critical Duocort Ab
Priority to SE0401031A priority Critical patent/SE0401031D0/xx
Publication of SE0401031D0 publication Critical patent/SE0401031D0/xx
Priority to CN201210499801.8A priority patent/CN103006592B/zh
Priority to PL16169413T priority patent/PL3072507T3/pl
Priority to EP05735076.1A priority patent/EP1744730B1/fr
Priority to AU2005235370A priority patent/AU2005235370B2/en
Priority to EP16169413.8A priority patent/EP3072507B1/fr
Priority to DK16169413.8T priority patent/DK3072507T3/da
Priority to BRPI0510044A priority patent/BRPI0510044B8/pt
Priority to PT57350761T priority patent/PT1744730T/pt
Priority to MEP-2016-250A priority patent/ME02584B/fr
Priority to CA2564000A priority patent/CA2564000C/fr
Priority to PL05735076T priority patent/PL1744730T3/pl
Priority to MX2013004889A priority patent/MX344197B/es
Priority to SI200532291T priority patent/SI3072507T1/sl
Priority to PT161694138T priority patent/PT3072507T/pt
Priority to DK05735076.1T priority patent/DK1744730T3/en
Priority to LTEP05735076.1T priority patent/LT1744730T/lt
Priority to ES05735076.1T priority patent/ES2600556T3/es
Priority to ES16169413T priority patent/ES2857600T3/es
Priority to NZ585340A priority patent/NZ585340A/en
Priority to SG2013005244A priority patent/SG188081A1/en
Priority to RS20210233A priority patent/RS61501B1/sr
Priority to HUE05735076A priority patent/HUE030546T2/en
Priority to JP2007508863A priority patent/JP5149618B2/ja
Priority to HRP20161380TT priority patent/HRP20161380T1/hr
Priority to HUE16169413A priority patent/HUE053248T2/hu
Priority to RS20160749A priority patent/RS55198B1/sr
Priority to MXPA06012011A priority patent/MXPA06012011A/es
Priority to LTEP16169413.8T priority patent/LT3072507T/lt
Priority to US11/587,514 priority patent/US8425937B2/en
Priority to PCT/EP2005/004400 priority patent/WO2005102271A2/fr
Priority to CN2005800118623A priority patent/CN1942176B/zh
Priority to IL178776A priority patent/IL178776A/en
Priority to ZA200609680A priority patent/ZA200609680B/xx
Priority to JP2012173158A priority patent/JP5681679B2/ja
Priority to US13/722,013 priority patent/US20130129823A1/en
Priority to HK13106780.6A priority patent/HK1179525B/xx
Priority to IL227375A priority patent/IL227375A/en
Priority to US14/255,332 priority patent/US10583146B2/en
Priority to CY20161101091T priority patent/CY1118275T1/el
Priority to HRP20210348TT priority patent/HRP20210348T1/hr
Priority to CY20211100191T priority patent/CY1124074T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SE0401031A 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy SE0401031D0 (sv)

Priority Applications (42)

Application Number Priority Date Filing Date Title
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
CN2005800118623A CN1942176B (zh) 2004-04-22 2005-04-21 用于糖皮质激素替代疗法的药物组合物
SG2013005244A SG188081A1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
RS20210233A RS61501B1 (sr) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida
EP05735076.1A EP1744730B1 (fr) 2004-04-22 2005-04-21 Compositions pharmaceutiques pour therapie de substitution par glucocorticoide
AU2005235370A AU2005235370B2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
EP16169413.8A EP3072507B1 (fr) 2004-04-22 2005-04-21 Compositions pharmaceutiques pour la thérapie de remplacement des glucocorticoïdes
DK16169413.8T DK3072507T3 (da) 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
BRPI0510044A BRPI0510044B8 (pt) 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica
PT57350761T PT1744730T (pt) 2004-04-22 2005-04-21 Composições farmacêuticas para terapia de substituição de glucocorticoide
MEP-2016-250A ME02584B (fr) 2004-04-22 2005-04-21 Compositions pharmaceutiques pour therapie de substitution par glucocorticoide
CA2564000A CA2564000C (fr) 2004-04-22 2005-04-21 Compositions pharmaceutiques pour therapie de substitution par glucocorticoide
PL05735076T PL1744730T3 (pl) 2004-04-22 2005-04-21 Kompozycje farmaceutyczne do glikokortykoidowej terapii zastępczej
MX2013004889A MX344197B (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
SI200532291T SI3072507T1 (sl) 2004-04-22 2005-04-21 Farmacevtski sestavek za nadomestno zdravljenje z glukokortikoidi
PT161694138T PT3072507T (pt) 2004-04-22 2005-04-21 Composições farmacêuticas para terapia de substituição de glucocorticóide
DK05735076.1T DK1744730T3 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
LTEP05735076.1T LT1744730T (lt) 2004-04-22 2005-04-21 Farmacinės kompozicijos, skirtos pakaitinei gliukokortikoidų terapijai
ES05735076.1T ES2600556T3 (es) 2004-04-22 2005-04-21 Sustitución de las composiciones farmacéuticas para la terapia con glucocorticoides
ES16169413T ES2857600T3 (es) 2004-04-22 2005-04-21 Composiciones farmacéuticas para terapia de reemplazo con glucocorticoides
NZ585340A NZ585340A (en) 2004-04-22 2005-04-21 Coated tablet composition comprising a coat for immediate release glucocorticoid and a core for extended release glucocorticoid for glucocorticoid replacement therapy
CN201210499801.8A CN103006592B (zh) 2004-04-22 2005-04-21 用于糖皮质激素替代疗法的药物组合物
JP2007508863A JP5149618B2 (ja) 2004-04-22 2005-04-21 グルココルチコイド代償療法用の医薬組成物
PL16169413T PL3072507T3 (pl) 2004-04-22 2005-04-21 Kompozycje farmaceutyczne do glikokortykoidowej terapii zastępczej
HUE05735076A HUE030546T2 (en) 2004-04-22 2005-04-21 A pharmaceutical composition for glucocorticoid replacement therapy
HRP20161380TT HRP20161380T1 (hr) 2004-04-22 2005-04-21 Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
HUE16169413A HUE053248T2 (hu) 2004-04-22 2005-04-21 Gyógyszerészeti készítmények glükokortikoid helyettesítõ terápiára
RS20160749A RS55198B1 (sr) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida
MXPA06012011A MXPA06012011A (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
LTEP16169413.8T LT3072507T (lt) 2004-04-22 2005-04-21 Farmacinės kompozicijos, skirtos pakaitinei gliukokortikoidų terapijai
US11/587,514 US8425937B2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (fr) 2004-04-22 2005-04-21 Compositions pharmaceutiques pour therapie de substitution par glucocorticoide
IL178776A IL178776A (en) 2004-04-22 2006-10-19 Dosage form of tablet coated with glucocorticoid replacement therapy
ZA200609680A ZA200609680B (en) 2004-04-22 2006-11-21 Pharmaceutical compositions for glucocorticoid replacement therapy
JP2012173158A JP5681679B2 (ja) 2004-04-22 2012-08-03 グルココルチコイド代償療法用の医薬組成物
US13/722,013 US20130129823A1 (en) 2004-04-22 2012-12-20 Pharmaceutical compositions for glucocorticoid replacement therapy
HK13106780.6A HK1179525B (en) 2004-04-22 2013-06-07 Pharmaceutical compositions for glucocorticoid replacement therapy
IL227375A IL227375A (en) 2004-04-22 2013-07-08 Dosage form of tablet coated with glucocorticoid replacement therapy
US14/255,332 US10583146B2 (en) 2004-04-22 2014-04-17 Pharmaceutical compositions for glucocorticoid replacement therapy
CY20161101091T CY1118275T1 (el) 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
HRP20210348TT HRP20210348T1 (hr) 2004-04-22 2021-03-01 Farmaceutski sastavi za terapiju zamjene glukokortikoida
CY20211100191T CY1124074T1 (el) 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
SE0401031D0 true SE0401031D0 (sv) 2004-04-22

Family

ID=35197481

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy

Country Status (25)

Country Link
US (3) US8425937B2 (fr)
EP (2) EP3072507B1 (fr)
JP (2) JP5149618B2 (fr)
CN (2) CN1942176B (fr)
AU (1) AU2005235370B2 (fr)
BR (1) BRPI0510044B8 (fr)
CA (1) CA2564000C (fr)
CY (2) CY1118275T1 (fr)
DK (2) DK3072507T3 (fr)
ES (2) ES2857600T3 (fr)
HR (2) HRP20161380T1 (fr)
HU (2) HUE030546T2 (fr)
IL (2) IL178776A (fr)
LT (2) LT3072507T (fr)
ME (1) ME02584B (fr)
MX (2) MX344197B (fr)
NZ (1) NZ585340A (fr)
PL (2) PL1744730T3 (fr)
PT (2) PT3072507T (fr)
RS (2) RS55198B1 (fr)
SE (1) SE0401031D0 (fr)
SG (1) SG188081A1 (fr)
SI (1) SI3072507T1 (fr)
WO (1) WO2005102271A2 (fr)
ZA (1) ZA200609680B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1744760B1 (fr) * 2004-04-22 2015-01-07 AcuCort AB Compositions pharmaceutiques pour therapie aux glucocorticoides aigue
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
CA2630261A1 (fr) * 2005-12-06 2007-06-14 Monosol Rx, Llc Compositions de films topiques pour la liberation d'actifs
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
ES2358158T3 (es) * 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
WO2010115615A1 (fr) * 2009-04-07 2010-10-14 Duocort Pharma Ab Amélioration de la thérapie par les glucocorticoïdes
AU2011254959A1 (en) 2010-05-20 2013-01-10 Duocort Pharma Ab Posology and administration of glucocorticoid based compositions
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
EA032515B1 (ru) 2012-11-02 2019-06-28 Марри Энд Пул Энтерпрайзес, Лтд. Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
US20160081936A1 (en) 2013-04-16 2016-03-24 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
ES2716990T5 (es) 2013-12-23 2023-03-24 Dr Falk Pharma Gmbh Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
WO2026052804A1 (fr) 2024-09-06 2026-03-12 Institut National de la Santé et de la Recherche Médicale Film dispersible oral à base d'hydrocortisone et ses utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
JP3122141B2 (ja) * 1994-01-31 2001-01-09 山之内製薬株式会社 口腔内溶解型圧縮成型物及びその製造法
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
NZ527832A (en) 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
WO2002074316A1 (fr) * 2001-03-15 2002-09-26 Enteron Pharmaceuticals, Inc. Methode de traitement de troubles inflammatoires du tractus gastro-intestinal au moyen de corticosteroides a action topique
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PL372290A1 (en) 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
EP1744760B1 (fr) 2004-04-22 2015-01-07 AcuCort AB Compositions pharmaceutiques pour therapie aux glucocorticoides aigue
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
WO2010115615A1 (fr) 2009-04-07 2010-10-14 Duocort Pharma Ab Amélioration de la thérapie par les glucocorticoïdes
AU2011254959A1 (en) 2010-05-20 2013-01-10 Duocort Pharma Ab Posology and administration of glucocorticoid based compositions

Also Published As

Publication number Publication date
EP1744730A2 (fr) 2007-01-24
ES2600556T3 (es) 2017-02-09
LT1744730T (lt) 2016-10-25
IL227375A (en) 2017-08-31
CY1124074T1 (el) 2022-03-24
WO2005102271A3 (fr) 2006-08-03
BRPI0510044B8 (pt) 2021-05-25
HRP20210348T1 (hr) 2021-04-16
JP5149618B2 (ja) 2013-02-20
ME02584B (fr) 2017-06-20
HRP20161380T1 (hr) 2016-12-02
BRPI0510044B1 (pt) 2019-01-29
CA2564000C (fr) 2013-07-02
PL1744730T3 (pl) 2017-01-31
CY1118275T1 (el) 2017-06-28
NZ585340A (en) 2012-04-27
ES2857600T3 (es) 2021-09-29
CN103006592A (zh) 2013-04-03
RS55198B1 (sr) 2017-01-31
CN103006592B (zh) 2016-03-02
PT3072507T (pt) 2021-02-23
US20140242167A1 (en) 2014-08-28
HUE030546T2 (en) 2017-05-29
US20130129823A1 (en) 2013-05-23
HUE053248T2 (hu) 2021-06-28
PL3072507T3 (pl) 2021-07-19
AU2005235370B2 (en) 2011-06-09
PT1744730T (pt) 2016-10-07
WO2005102271A2 (fr) 2005-11-03
IL178776A0 (en) 2007-02-11
DK1744730T3 (en) 2016-08-29
LT3072507T (lt) 2021-02-25
MXPA06012011A (es) 2007-04-16
EP3072507B1 (fr) 2020-12-23
JP2012236846A (ja) 2012-12-06
RS61501B1 (sr) 2021-03-31
BRPI0510044A (pt) 2007-10-16
ZA200609680B (en) 2008-08-27
AU2005235370A1 (en) 2005-11-03
CA2564000A1 (fr) 2005-11-03
SG188081A1 (en) 2013-03-28
HK1179525A1 (zh) 2013-10-04
EP3072507A1 (fr) 2016-09-28
SI3072507T1 (sl) 2021-04-30
US20080187586A1 (en) 2008-08-07
CN1942176A (zh) 2007-04-04
US10583146B2 (en) 2020-03-10
CN1942176B (zh) 2013-09-18
IL178776A (en) 2013-10-31
MX344197B (es) 2016-12-08
JP5681679B2 (ja) 2015-03-11
EP1744730B1 (fr) 2016-08-03
DK3072507T3 (da) 2021-02-08
JP2007533698A (ja) 2007-11-22
US8425937B2 (en) 2013-04-23

Similar Documents

Publication Publication Date Title
SE0401031D0 (sv) A new glucocorticoid replacement therapy
Chen et al. Calcium hydroxide–induced proliferation, migration, osteogenic differentiation, and mineralization via the mitogen-activated protein kinase pathway in human dental pulp stem cells
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l'osteoformation et l'autorenouvellement des cellules
ATE544460T1 (de) Zusammensetzungen und verfahren für eine gesunde schwangerschaft
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
TNSN07005A1 (fr) Analogues tetrapeptidiques
Becker et al. Quality of life in oral cancer patients–effects of mandible resection and socio-cultural aspects
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
WO2006014678A3 (fr) Compositions et methodes d'utilisation de la proteine 4 analogue a l'angiopoietine
Wang et al. Mineral trioxide aggregate enhances the osteogenic capacity of periodontal ligament stem cells via NF‐κB and MAPK signaling pathways
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EP1885371A4 (fr) Compositions therapeutiques et methodes associees
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
WO2006102979A3 (fr) Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires
Faccioni et al. Short‐term “in vivo” study on cellular DNA damage induced by acrylic Andresen activator in oral mucosa cells